FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3096871612> ?p ?o ?g. }

• W3096871612 endingPage "40" @default.
• W3096871612 startingPage "39" @default.
• W3096871612 abstract "MRD in ALL is defined as the detection of leukemic cells in bone marrow below the microscopic threshold in complete remission (CR). Patients (pts) with molecular failure (MolFail) or molecular relapse (MolRel) after induction/consolidation therapy are at a high risk for hematologic relapse. Targeted therapies should prevent hematologic relapse, reduce MRD load and provide a bridging strategy to allogeneic stem cell transplantation (SCT) and thereby improve overall outcome of these pts. In pts without (wo) SCT option reduction of MRD load is an essential goal as well. Blinatumomab is an antibody construct that redirects CD3+ T cells to CD19+ target cells, resulting in a serial lysis of CD19+ B cells. In a study in pts with MRD ≥10-3, 78% achieved complete MRD response (Gökbuget N et al., Blood 2018). The MolAct1 trial was initiated by the GMALL study group to evaluate the efficacy and tolerability of Blinatumomab in MRD+ ALL including those with MRD below 10-3 and pts with MRD after SCT. Adults (≥18 yrs) with CD19+, Ph-negative BCP ALL in CR after ≥ 3 chemotherapies with MRD ≥10-4 were eligible (NCT03109093). Recruitment of pts with MRD ≥10-3 was stopped after marketing authorization for this entity. After an amendment, which became effective after 44 recruited pts, pts with MRD below 10-4 or non-quantifiable (nq) MRD were eligible. Blinatumomab 28 μg/day was given as 4-wk infusion, followed by a 2-wk break (1 cycle). Responders could receive up to 4 cycles or undergo HSCT after ≥ 1 cycle. MRD after 1 cycle was the primary endpoint. MRD was centrally assessed by allele-specific quantitative real-time PCR of clonal rearrangements of immunoglobulin or T-cell receptor genes. For definition of MRD at inclusion and at response assessment see table 1. 64 pts with a median age of 44 (18-83) yrs were included from 19 centers and 60 were evaluable. 63 pts were treated in first CR (5 after SCT). Overall, 67% achieved MolCR, 10% had MolFail, 23% MolNE. MolNE identifies an intermediate response with different options clarified table 1. 81% of the pts included with MRD ≥10-4 had a molecular response i.e. MolCR or MRD &lt; 10-4. No significant differences in terms of MRD response were observed according to MRD level at inclusion or other patient characteristics (table 1). 60 pts have completed study treatment (40 HSCT, 8 relapses during treatment, 4 completed 4 cycles wo SCT, 2 stopped earlier due to toxicities - 1 with subsequent SCT, 1 due to GvHD, 1 due to physicians' decision and 4 pts returned to standard treatment after 2 cycles). SCT pts had a median age of 42 (18-66) yrs and follow-up is available in 37 / 41 pts (29 CCR, 3 relapse, 5 death in CR). 16 relapses occurred: 8 during treatment (1 after MolCR, 5 MolNE1-3 and 2 with MolFail resp); after SCT in 3/41 pts; 5/11 with CR at end of treatment wo subsequent SCT. The median observation time of surviving pts is 12 (1-38) mo and the median survival is not reached. At 2 yrs the survival probability (OS) was 64%. OS was 70%, 64% and 43% in pts with MRD between 10-4-10-3, 10-3-10-2 and &gt;10-2 at inclusion, resp (p&gt;.05; Fig.1). OS was 71% vs 54% in pts MolFail vs MolRel at inclusion (p&gt;.05). OS was 72%, 40% and 56% in pts with MolCR, MolFail and MolNE after cycle 1 resp (P=0.02; Fig.2). Overall, the results from previous trials were confirmed. In addition, it was demonstrated that pts with MRD between 10-4 and 10-3 had a similar response and a trend towards better outcome compared to pts with higher MRD levels &gt;10-2. So far only 7 pts with MRD below 10-4 were included; more data are needed to evaluate the impact of Blinatumomab in this population; GMALL does currently not recommend SCT for these pts unless there is an indication due to other risk factors. Interestingly, a significant proportion of pts (23%) had an incomplete MRD response and the outcome results indicate that these pts together with those with MolFail may have an inferior survival compared to those with MolCR. The results underline that the clear definition of MRD categories and consideration of level and sensitivity is essential for interpretation, which is possible due to well defined standards for the PCR method used here. 68% of the pts received SCT in CR after Blinatumomab with a so far limited mortality (13%). Further follow-up is certainly required. The GMALL will continue to recruit patients with MRD levels below 10-3 in order to improve their chances for long-term survival This study was supported by Amgen Inc. Disclosures Goekbuget: Servier: Consultancy, Research Funding; Jazz: Consultancy, Research Funding; Pfizer: Consultancy, Research Funding; Novartis: Consultancy, Research Funding; Amgen: Consultancy, Research Funding; Erytech: Consultancy; Kite: Consultancy; Gilead: Consultancy. Schwartz:Pfizer: Other: personal fees ; AMGEN: Other: personal fees and non-financial support; BTG Intl Inc: Other: personal fees ; Gilead Sciences: Other: personal fees and non-financial support ; MSD Sharp & Dohme: Other: personal fees ; Basilea: Other: non-financial suppor; Novartis: Other: personal fees and non-financial support; Jazz Pharmaceuticals: Other: personal fees and non-financial support. Hüttmann:Lead Discovery Center GmbH: Consultancy; University Hospital Essen, University of Duisburg-Essen, Essen, Germany: Current Employment; Celgene: Honoraria, Other: TRAVEL, ACCOMMODATIONS, EXPENSES (paid by any for-profit health care company); Seattle Genetics: Research Funding; Roche: Other: Travel expenses; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: TRAVEL, ACCOMMODATIONS, EXPENSES (paid by any for-profit health care company); Gilead: Honoraria. Viardot:Roche: Honoraria, Other: advisory board; Kite/Gilead: Honoraria, Other: advisory board; Novartis: Honoraria, Other: advisory board; Amgen: Honoraria, Other: advisory board. Fiedler:Daiichi Sankyo: Other: support for meeting attendance; Gilead: Other: support for meeting attendance; Jazz Pharmaceuticals: Honoraria, Other: support for meeting attendance; Abbvie: Membership on an entity's Board of Directors or advisory committees; Morphosys: Consultancy, Honoraria; Celgene: Membership on an entity's Board of Directors or advisory committees; Pfizer: Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Consultancy, Honoraria; ARIAD/Incyte: Consultancy, Honoraria; Amgen: Consultancy, Honoraria, Other: support for meeting attendance, Patents & Royalties, Research Funding. Alakel:Pfizer: Consultancy. Stelljes:Pfizer: Consultancy, Honoraria, Research Funding, Speakers Bureau; Amgen: Consultancy, Speakers Bureau. Subklewe:Seattle Genetics: Research Funding; AMGEN: Consultancy, Honoraria, Research Funding; Morphosys: Research Funding; Gilead Sciences: Consultancy, Honoraria, Research Funding; Celgene: Consultancy, Honoraria; Novartis: Consultancy, Research Funding; Pfizer: Consultancy, Honoraria; Janssen: Consultancy; Roche AG: Consultancy, Research Funding. Wäsch:Pfizer: Consultancy; Amgen: Consultancy; Janssen: Consultancy. Vucinic:Celgene: Honoraria. Fransecky:Amgen: Consultancy. Bargou:Amgen: Consultancy, Honoraria, Patents & Royalties; Gemoab: Consultancy, Honoraria; Cellex: Consultancy, Honoraria; Catalym: Consultancy, Honoraria. Topp:Amgen, Boehringer Ingelheim, KITE, Regeneron, Roche: Research Funding; Amgen, KITE, Novartis, Regeneron, Roche: Consultancy. Brüggemann:Regeneron: Research Funding; Amgen: Consultancy, Honoraria, Research Funding; Celgene: Consultancy; Incyte: Consultancy; Roche: Consultancy; Affimed: Research Funding; Janssen: Consultancy, Honoraria. OffLabel Disclosure: Blinatumomab in MRD positive disease below 10-3" @default.
• W3096871612 created "2020-11-09" @default.
• W3096871612 creator A5003069482 @default.
• W3096871612 creator A5006288618 @default.
• W3096871612 creator A5019221316 @default.
• W3096871612 creator A5019602816 @default.
• W3096871612 creator A5029898558 @default.
• W3096871612 creator A5030329628 @default.
• W3096871612 creator A5035072666 @default.
• W3096871612 creator A5039023052 @default.
• W3096871612 creator A5040594919 @default.
• W3096871612 creator A5043174640 @default.
• W3096871612 creator A5047060286 @default.
• W3096871612 creator A5057678118 @default.
• W3096871612 creator A5059188766 @default.
• W3096871612 creator A5062937497 @default.
• W3096871612 creator A5066528064 @default.
• W3096871612 creator A5067716137 @default.
• W3096871612 creator A5069689988 @default.
• W3096871612 creator A5075073484 @default.
• W3096871612 creator A5080023449 @default.
• W3096871612 creator A5082867129 @default.
• W3096871612 creator A5084039929 @default.
• W3096871612 creator A5086016311 @default.
• W3096871612 creator A5088238455 @default.
• W3096871612 creator A5091739351 @default.
• W3096871612 date "2020-11-05" @default.
• W3096871612 modified "2023-10-14" @default.
• W3096871612 title "Interim Results of a Multicenter, Single-Arm Study to Assess Blinatumomab in Adult Patients (pts) with Minimal Residual Disease (MRD) of B-Precursor (BCP) Acute Lymphoblastic Leukemia (GMALL-MOLACT1-BLINA)" @default.
• W3096871612 doi "https://doi.org/10.1182/blood-2020-137350" @default.
• W3096871612 hasPublicationYear "2020" @default.
• W3096871612 type Work @default.
• W3096871612 sameAs 3096871612 @default.
• W3096871612 citedByCount "4" @default.
• W3096871612 countsByYear W30968716122021 @default.
• W3096871612 countsByYear W30968716122022 @default.
• W3096871612 countsByYear W30968716122023 @default.
• W3096871612 crossrefType "journal-article" @default.
• W3096871612 hasAuthorship W3096871612A5003069482 @default.
• W3096871612 hasAuthorship W3096871612A5006288618 @default.
• W3096871612 hasAuthorship W3096871612A5019221316 @default.
• W3096871612 hasAuthorship W3096871612A5019602816 @default.
• W3096871612 hasAuthorship W3096871612A5029898558 @default.
• W3096871612 hasAuthorship W3096871612A5030329628 @default.
• W3096871612 hasAuthorship W3096871612A5035072666 @default.
• W3096871612 hasAuthorship W3096871612A5039023052 @default.
• W3096871612 hasAuthorship W3096871612A5040594919 @default.
• W3096871612 hasAuthorship W3096871612A5043174640 @default.
• W3096871612 hasAuthorship W3096871612A5047060286 @default.
• W3096871612 hasAuthorship W3096871612A5057678118 @default.
• W3096871612 hasAuthorship W3096871612A5059188766 @default.
• W3096871612 hasAuthorship W3096871612A5062937497 @default.
• W3096871612 hasAuthorship W3096871612A5066528064 @default.
• W3096871612 hasAuthorship W3096871612A5067716137 @default.
• W3096871612 hasAuthorship W3096871612A5069689988 @default.
• W3096871612 hasAuthorship W3096871612A5075073484 @default.
• W3096871612 hasAuthorship W3096871612A5080023449 @default.
• W3096871612 hasAuthorship W3096871612A5082867129 @default.
• W3096871612 hasAuthorship W3096871612A5084039929 @default.
• W3096871612 hasAuthorship W3096871612A5086016311 @default.
• W3096871612 hasAuthorship W3096871612A5088238455 @default.
• W3096871612 hasAuthorship W3096871612A5091739351 @default.
• W3096871612 hasConcept C11413529 @default.
• W3096871612 hasConcept C126322002 @default.
• W3096871612 hasConcept C155512373 @default.
• W3096871612 hasConcept C17744445 @default.
• W3096871612 hasConcept C187212893 @default.
• W3096871612 hasConcept C199539241 @default.
• W3096871612 hasConcept C2776957806 @default.
• W3096871612 hasConcept C2778020697 @default.
• W3096871612 hasConcept C2778461978 @default.
• W3096871612 hasConcept C2779823535 @default.
• W3096871612 hasConcept C2781107101 @default.
• W3096871612 hasConcept C2909962599 @default.
• W3096871612 hasConcept C33923547 @default.
• W3096871612 hasConcept C71924100 @default.
• W3096871612 hasConceptScore W3096871612C11413529 @default.
• W3096871612 hasConceptScore W3096871612C126322002 @default.
• W3096871612 hasConceptScore W3096871612C155512373 @default.
• W3096871612 hasConceptScore W3096871612C17744445 @default.
• W3096871612 hasConceptScore W3096871612C187212893 @default.
• W3096871612 hasConceptScore W3096871612C199539241 @default.
• W3096871612 hasConceptScore W3096871612C2776957806 @default.
• W3096871612 hasConceptScore W3096871612C2778020697 @default.
• W3096871612 hasConceptScore W3096871612C2778461978 @default.
• W3096871612 hasConceptScore W3096871612C2779823535 @default.
• W3096871612 hasConceptScore W3096871612C2781107101 @default.
• W3096871612 hasConceptScore W3096871612C2909962599 @default.
• W3096871612 hasConceptScore W3096871612C33923547 @default.
• W3096871612 hasConceptScore W3096871612C71924100 @default.
• W3096871612 hasIssue "Supplement 1" @default.
• W3096871612 hasLocation W30968716121 @default.
• W3096871612 hasOpenAccess W3096871612 @default.
• W3096871612 hasPrimaryLocation W30968716121 @default.
• W3096871612 hasRelatedWork W2080740135 @default.
• W3096871612 hasRelatedWork W2547353143 @default.
• W3096871612 hasRelatedWork W2576962736 @default.
• W3096871612 hasRelatedWork W2593458633 @default.

• next